Shionogi strengthens rare disease strategy with planned Radicava deal
Tanabe Pharma plans to establish a new U.S.-based company to hold the global rights to Radicava and Radicava…
Articles by Margarida Maia, PhD
Open dialogue is key to better psychological support in ALS: Study
Both people living with amyotrophic lateral sclerosis (ALS) and their caregivers benefit most from flexible, personalized psychological support that…
QRL-101 reduces motor-neuron hyperexcitability in ALS trial
QRL-101, an experimental oral small molecule being developed by Quralis for amyotrophic lateral sclerosis (ALS), was found in…
Top 10 ALS news stories of 2025
Throughout 2025, ALS News Today delivered readers timely reporting on research breakthroughs, patient advocacy, potential treatments, and diagnostic advances…
Actor Eric Dane joins Target ALS board after his own diagnosis
Actor Eric Dane, who is living with amyotrophic lateral sclerosis (ALS), has joined the board of directors of…
Actor Eric Dane pushes for ALS research: Not ‘the end of my story’
Actor Eric Dane is teaming up with Target ALS on a campaign to raise $500,000 by Dec. 31 to…
FDA authorizes new Phase 3 clinical trial of PrimeC for ALS
The U.S. Food and Drug Administration (FDA) has authorized Neurosense Therapeutics to begin a pivotal Phase 3 trial of…
Researchers find way to make diagnosis of ALS more accurate
Combining two blood biomarkers may make the diagnosis of amyotrophic lateral sclerosis (ALS) more accurate and help predict how…
Cost of ALS care in US in first year tops $47K for Medicare users
People with amyotrophic lateral sclerosis (ALS) spend upward of $47,000 on medical care during the first year after their…
Head trauma may be an early sign, not a cause of ALS: Study
People with a history of traumatic brain injury (TBI) have a nearly three times higher risk of developing amyotrophic…